Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

PubWeight™: 4.44‹?› | Rank: Top 1%

🔗 View Article (PMID 22547592)

Published in J Clin Oncol on April 30, 2012

Authors

Thomas J Lynch1, Igor Bondarenko, Alexander Luft, Piotr Serwatowski, Fabrice Barlesi, Raju Chacko, Martin Sebastian, Joel Neal, Haolan Lu, Jean-Marie Cuillerot, Martin Reck

Author Affiliations

1: Yale Cancer Center and Smilow Cancer Hospital, New Haven, CT, USA. thomas.lynch@yale.edu

Articles citing this

(truncated to the top 100)

Comprehensive genomic characterization of squamous cell lung cancers. Nature (2012) 18.90

Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell (2015) 5.10

Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol (2015) 4.25

Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun (2013) 2.94

Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol (2013) 2.64

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol (2013) 2.35

An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res (2013) 2.30

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci (2013) 2.03

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. J Clin Oncol (2016) 1.70

Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest (2015) 1.67

Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J Transl Med (2012) 1.60

Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol (2015) 1.54

Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res (2013) 1.53

Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology (2015) 1.53

What have we learned from cancer immunotherapy in the last 3 years? J Transl Med (2014) 1.52

Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer. Cancer Immunol Res (2013) 1.47

The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy. Blood (2015) 1.47

Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol Res (2014) 1.43

Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2013) 1.41

Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer (2014) 1.35

Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov (2016) 1.34

Cancer immunotherapy: the beginning of the end of cancer? BMC Med (2016) 1.32

Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology (2013) 1.31

Targeted therapy for non-small-cell lung cancer: past, present and future. Expert Rev Anticancer Ther (2013) 1.22

Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol (2015) 1.21

Molecular pathways and therapeutic targets in lung cancer. Oncotarget (2014) 1.16

Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. Clin Cancer Res (2016) 1.15

Immune modulation for cancer therapy. Br J Cancer (2014) 1.15

Big opportunities for small molecules in immuno-oncology. Nat Rev Drug Discov (2015) 1.12

Chemoimmunotherapy: reengineering tumor immunity. Cancer Immunol Immunother (2013) 1.11

Lung tumor NF-κB signaling promotes T cell-mediated immune surveillance. J Clin Invest (2013) 1.08

Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. PLoS One (2013) 1.08

Immunotherapy advances for glioblastoma. Neuro Oncol (2014) 1.07

Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment. Eur J Radiol (2015) 1.07

The Evolution of Therapies in Non-Small Cell Lung Cancer. Cancers (Basel) (2015) 1.06

The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res (2015) 1.04

Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? J Immunother Cancer (2014) 1.04

Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer. J Thorac Dis (2013) 1.03

Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity. Cancer Immunol Res (2013) 1.03

Lung cancer: Biology and treatment options. Biochim Biophys Acta (2015) 1.02

A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy. Comput Struct Biotechnol J (2015) 1.00

Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res (2016) 0.99

Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies. Transl Lung Cancer Res (2015) 0.99

Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs (2014) 0.99

Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest (2015) 0.98

Intratumoral anti-HuD immunotoxin therapy for small cell lung cancer and neuroblastoma. J Hematol Oncol (2014) 0.97

State of the art: Response assessment in lung cancer in the era of genomic medicine. Radiology (2014) 0.97

Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol (2015) 0.97

Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses. Mol Ther (2015) 0.97

Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer. Ann Oncol (2013) 0.96

Advances in immunotherapy for treatment of lung cancer. Cancer Biol Med (2015) 0.95

Small cell lung cancer: will recent progress lead to improved outcomes? Clin Cancer Res (2015) 0.94

Novel antibodies targeting immune regulatory checkpoints for cancer therapy. Br J Clin Pharmacol (2013) 0.94

VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy. Cancer Immunol Res (2014) 0.94

Immunotherapy for Lung Cancer: Has it Finally Arrived? Front Oncol (2014) 0.94

The role of myeloid cells in cancer therapies. Nat Rev Cancer (2016) 0.92

In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. Vaccine (2015) 0.92

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol (2017) 0.91

Trial Watch: Radioimmunotherapy for oncological indications. Oncoimmunology (2014) 0.91

Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models. Cancer Immunol Immunother (2013) 0.90

Immunotherapy for lung cancer: advances and prospects. Am J Clin Exp Immunol (2016) 0.89

Overview of current immunotherapeutic strategies for glioma. Immunotherapy (2015) 0.89

New strategies in immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res (2015) 0.89

Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types. Onco Targets Ther (2015) 0.88

Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment. BMC Cancer (2012) 0.88

Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer. Invest New Drugs (2015) 0.88

Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. J Thorac Oncol (2015) 0.87

Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome. J Immunother Cancer (2014) 0.87

Ipilimumab: its potential in non-small cell lung cancer. Ther Adv Med Oncol (2012) 0.87

Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer? Semin Oncol (2013) 0.87

Update in lung cancer and mesothelioma 2012. Am J Respir Crit Care Med (2013) 0.87

COPD and squamous cell lung cancer: aberrant inflammation and immunity is the common link. Br J Pharmacol (2015) 0.87

The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer. PLoS One (2013) 0.86

Targeted therapies in non-small cell lung carcinoma: what have we achieved so far? Ther Adv Med Oncol (2013) 0.86

Adenocarcinoma contains more immune tolerance regulatory t-cell lymphocytes (versus squamous carcinoma) in non-small-cell lung cancer. Lung (2013) 0.86

Targeting PD-1/PD-L1 in lung cancer: current perspectives. Lung Cancer (Auckl) (2015) 0.86

Clinical significance of expanded Foxp3+ Helios- regulatory T cells in patients with non-small cell lung cancer. Int J Oncol (2015) 0.85

Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int (2016) 0.85

Immune checkpoint inhibitors in NSCLC. Curr Treat Options Oncol (2014) 0.85

The past, present and future of immunotherapy against tumor. Transl Lung Cancer Res (2015) 0.85

Hispanic accrual on randomized cancer clinical trials: a call to arms. J Clin Oncol (2014) 0.85

Immunotherapy prospects in the treatment of lung cancer and mesothelioma. Transl Lung Cancer Res (2014) 0.85

Novel therapies in small cell lung cancer. Transl Lung Cancer Res (2015) 0.84

Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. J Crohns Colitis (2016) 0.84

Treatment of advanced squamous cell carcinoma of the lung: a review. Transl Lung Cancer Res (2015) 0.84

Immuno-oncology combinations: raising the tail of the survival curve. Cancer Biol Med (2016) 0.84

Prognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer. J Ovarian Res (2016) 0.84

The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC). Ann Transl Med (2015) 0.84

Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer (2014) 0.83

Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients. J Immunother Cancer (2016) 0.83

A phase I study of MEDI4736, NNT-PD-L1 antibody in patients with advanced solid tumors. Transl Lung Cancer Res (2014) 0.83

NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy. J Transl Med (2015) 0.83

Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer. Onco Targets Ther (2016) 0.82

Immunotherapy for non-small cell lung cancer. Tuberc Respir Dis (Seoul) (2014) 0.82

Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora? Semin Immunopathol (2017) 0.82

Locally advanced lung cancer: an optimal setting for vaccines and other immunotherapies. Cancer J (2013) 0.82

Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy. Semin Oncol (2015) 0.82

Why has active immunotherapy not worked in lung cancer? Ann Oncol (2015) 0.82

Immunotherapy in lung cancer. Transl Lung Cancer Res (2014) 0.82

Evolving Concepts: Immunity in Oncology from Targets to Treatments. J Oncol (2015) 0.81

Articles by these authors

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol (2008) 17.30

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med (2015) 12.54

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med (2015) 11.98

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet (2008) 10.74

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol (2008) 9.98

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol (2011) 6.30

PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol (2013) 5.48

Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2013) 5.21

Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol (2007) 4.94

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 4.71

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol (2012) 4.29

Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol (2009) 4.27

Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol (2006) 3.52

Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol (2013) 3.48

Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol (2012) 3.28

Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol (2011) 3.24

Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol (2010) 3.13

Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol (2011) 2.92

Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol (2012) 2.44

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol (2013) 2.41

Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J Clin Oncol (2012) 2.07

Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol (2008) 1.92

Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol (2011) 1.88

A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors. Clin Cancer Res (2012) 1.83

Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol (2008) 1.74

Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol (2009) 1.71

Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. J Clin Oncol (2011) 1.63

Targeted therapies for non-small cell lung cancer. Lung Cancer (2009) 1.63

Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. J Clin Oncol (2012) 1.55

Outcomes after percutaneous coronary intervention of ostial lesions in the era of drug-eluting stents. Catheter Cardiovasc Interv (2009) 1.51

Diagnostics and staging procedures in non-small cell lung cancer - is less more? Clin Respir J (2008) 1.38

Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study. J Thorac Oncol (2008) 1.34

Synchronous multiple primary lung cancer: an increasing clinical occurrence requiring multidisciplinary management. J Thorac Cardiovasc Surg (2007) 1.33

Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J Clin Oncol (2009) 1.30

An evaluation of octogenarians undergoing percutaneous coronary intervention from the Melbourne Interventional Group registry. Catheter Cardiovasc Interv (2007) 1.29

Does the extent of lymph node dissection influence outcome in patients with stage I non-small-cell lung cancer? Eur J Cardiothorac Surg (2005) 1.28

Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy. BMC Cancer (2013) 1.26

Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Lung Cancer (2009) 1.21

T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment. Cancer Immunol Immunother (2012) 1.19

A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung. J Thorac Oncol (2010) 1.16

Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment. Radiat Oncol (2012) 1.12

Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. J Clin Oncol (2013) 1.12

Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials. Lung Cancer (2006) 1.12

A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. Lung Cancer (2009) 1.11

A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. Clin Cancer Res (2008) 1.08

Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals. J Immunol (2008) 1.08

Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol (2012) 1.07

Ep-CAM RNA expression predicts metastasis-free survival in three cohorts of untreated node-negative breast cancer. Breast Cancer Res Treat (2010) 1.05

Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers. Carcinogenesis (2008) 1.04

Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study. J Thorac Oncol (2008) 1.03

Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAiL). J Thorac Oncol (2010) 1.02

Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study. Lung Cancer (2011) 1.02

The prognostic impact of blood group-related antigen Lewis Y and the ABH blood groups in resected non-small cell lung cancer. Tumour Biol (2008) 1.00

A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015). J Thorac Oncol (2014) 1.00

Anesthetic influence on occurrence and treatment of the trigemino-cardiac reflex: a systematic literature review. Medicine (Baltimore) (2015) 1.00

One hundred consecutive pneumonectomies after induction therapy for non-small cell lung cancer: an uncertain balance between risks and benefits. J Thorac Cardiovasc Surg (2005) 1.00

Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study. J Thorac Oncol (2015) 0.99

First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology. Eur Respir Rev (2014) 0.99

Completion pneumonectomy in cancer patients: experience with 55 cases. Eur J Cardiothorac Surg (2004) 0.99

Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer. Lung Cancer (2012) 0.99

The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial. J Thorac Oncol (2010) 0.98

Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer. J Thorac Oncol (2008) 0.97

Tissue microarrays are reliable tools for the clinicopathological characterization of lung cancer tissue. Anticancer Res (2009) 0.96

Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTE. J Clin Oncol (2014) 0.96

Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390). J Thorac Oncol (2012) 0.95

Hyponatremia as prognostic factor in small cell lung cancer--a retrospective single institution analysis. Respir Med (2012) 0.95

Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. Cancer (2014) 0.95

Large cell neuroendocrine carcinoma of the lung: an aggressive disease potentially treatable with surgery. Ann Thorac Surg (2004) 0.94

Lactate dehydrogenase as prognostic factor in limited and extensive disease stage small cell lung cancer - a retrospective single institution analysis. Respir Med (2010) 0.94

A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer. Clin Cancer Res (2007) 0.94

Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol (2010) 0.94

Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial. J Thorac Oncol (2007) 0.93

The CareGiver Oncology Quality of Life questionnaire (CarGOQoL): development and validation of an instrument to measure the quality of life of the caregivers of patients with cancer. Eur J Cancer (2011) 0.92

An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer. J Thorac Oncol (2013) 0.92

Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer. Invest New Drugs (2014) 0.92

Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol (2010) 0.90

Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC. Target Oncol (2014) 0.89

Prevalence of the NOD2 3020insC mutation in aggregations of breast and lung cancer. Breast Cancer Res Treat (2006) 0.89

Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non-small-cell lung cancer prospectively stratified by beta-3 tubulin status. J Clin Oncol (2013) 0.89

Smoking related cancers and loci at chromosomes 15q25, 5p15, 6p22.1 and 6p21.33 in the Polish population. PLoS One (2011) 0.88

Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma. Cancer (2007) 0.88

Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer. Oncol Rep (2012) 0.88

Anaphylactic reaction to pemetrexed: a case report. J Pharm Pharm Sci (2014) 0.87

Ipilimumab: its potential in non-small cell lung cancer. Ther Adv Med Oncol (2012) 0.87

A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer. Clin Lung Cancer (2013) 0.87

Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies. Oncologist (2009) 0.86

Oral vinorelbine and cisplatin with concurrent radiotherapy after induction chemotherapy with cisplatin and docetaxel for patients with locally advanced non-small cell lung cancer: the GFPC 05-03 study. J Thorac Oncol (2011) 0.85

Targeted therapies in malignant pleural mesothelioma: a review of clinical studies. Anticancer Drugs (2011) 0.85

Long-term functional health status and exercise test variables for patients with pulmonary atresia with intact ventricular septum: a Congenital Heart Surgeons Society study. J Thorac Cardiovasc Surg (2013) 0.85

Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium. J Clin Oncol (2009) 0.84

Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer. J Thorac Oncol (2015) 0.84

Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis. Future Oncol (2014) 0.84

Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer (2014) 0.83

An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases. Lung Cancer (2012) 0.82

Surgical resection of liver non-small cell lung cancer metastasis: a dual weapon? Lung Cancer (2010) 0.82

Metronomics chemotherapy: time for computational decision support. Cancer Chemother Pharmacol (2014) 0.82